KalVista Pharmaceuticals, Inc.
kalvista.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2026 10-Q, filed May 14, 2026. Its latest SEC filing is a SCHEDULE 13G/A from Aug 14, 2026.
10-Q for Q1 FY2026, filed May 14, 2026
The sections below describe the company as of the FY2025 annual report.
What Did They Do?
Sells EKTERLY, an oral treatment for acute hereditary angioedema attacks, and develops other oral therapies for people with rare diseases.
10-K for FY2025, filed Jul 10, 2025
Who Were Their Customers?
EKTERLY is for people with HAE. KalVista licensed commercialization in Japan to Kaken and in Latin America to Multicare, and planned internal sales and marketing teams in major European markets.
10-K for FY2025, filed Jul 10, 2025 8-K, filed Jan 8, 2026We are a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by…View ↗
Provide access to sebetralstat globally through focused direct efforts and by entering commercialization agreements in certain locations.…View ↗
In April 2025, we entered into the Kaken Agreement with Kaken pursuant to which we have licensed exclusive commercialization rights in…View ↗
KalVista granted Multicare Pharmaceuticals, LLC exclusive rights to commercialize sebetralstat in Latin America. Multicare will be…View ↗
Did Revenues Turn Into Profits?
No. It lost $183.4M in FY2025.
10-K for FY2025, filed Jul 10, 2025
−$188MView ↗
10-K for FY2025, filed Jul 10, 2025
−$183.4MView ↗
10-K for FY2025, filed Jul 10, 2025
−$153.3MView ↗
How Were They Changing?
-
Jun 11, 2026
Chiesi completed its acquisition of KalVista
KalVista became a wholly owned subsidiary of Chiesi, and its shares ceased trading on Nasdaq.
Sources
8-K, filed Jun 11, 2026
Parma, Italy and Framingham, Mass., USA – 11 June, 2026 – Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical…View ↗
-
Apr 29, 2026
Chiesi agreed to acquire KalVista
The deal offered $27.00 per share in cash, subject to closing conditions.
Sources
8-K, filed Apr 29, 2026
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, among other things, Parent has agreed to cause…View ↗
From clinical development to an approved drug
The older report described a clinical-stage portfolio of oral candidates for HAE and DME, including an HAE prevention candidate and an eye-disease program. The latest report describes EKTERLY as approved and launched for acute HAE attacks, while retaining research programs in HAE and Factor XIIa inhibitors.
10-K for FY2022, filed Jul 7, 2022 10-K for FY2025, filed Jul 10, 2025We are a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease…View ↗
KVD824 is our oral product candidate being developed for potential prophylactic treatment of HAE. We are currently conducting the Phase 2…View ↗
Our DME program to date has been focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor…View ↗
We are a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by…View ↗
Position EKTERLY (sebetralstat) to become a foundational therapy for HAE. We launched EKTERLY (sebetralstat) for the treatment of acute…View ↗
Develop a sustainable pipeline by employing our internal scientific expertise while also planning for growth by evaluating strategic…View ↗
Who Did They Compete With?
Competes with Takeda, CSL Behring, Pharming Group, BioCryst Pharmaceuticals, Pharvaris, Intellia Therapeutics, BioMarin Pharmaceutical, Astria Therapeutics, ADARx Pharmaceuticals, and Ionis Pharmaceuticals
10-K for FY2025, filed Jul 10, 2025In treating HAE, we expect to face competition from several FDA-approved therapeutics for both prophylactic and on-demand usage. All…View ↗
Loading...
